ALK-Abelló
162.3
DKK
-2.46 %
ALK B
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
15 following
-2.46%
-0.79%
-7.78%
+6.15%
+60.38%
+76.89%
+1.06%
+98.29%
+370.43%
ir.alk.net
ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,900 people worldwide and is listed on Nasdaq Copenhagen.
Revenue
4.82B
EBIT %
13.81 %
P/E
73.77
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Copenhagen
ALK B
Daily low / high price
161.7 / 167.9
DKK
Market cap
36.16B DKK
Turnover
25.06M DKK
Volume
154K
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| The Lundbeck Foundation | 40.3 % | 67.2 % |
| The Danish Labour Market Supplementary Pension ( ATP) | 7.5 % | 4.1 % |
| ALK - own shares | 1.9 % | 1.9 % |
ShowingAll content types
ALK – Opdatering på de første 9 måneder i 2024 og ny strategisk licensaftale med ARS Pharma
Nine-month interim report (Q3) 2024 (unaudited)
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Nine-month interim report (Q3) 2024 (unaudited) - English version only
ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)
ALK indlicenserer rettigheder til neffy®, den første godkendte næsespray med adrenalin til akut behandling af allergiske reaktioner (anafylaksi)
Invitation til præsentation af ALK’s regnskab for de første ni måneder (Q3) 2024 torsdag den 14. november 2024
Invitation to the presentation of ALK’s results for the first nine months (Q3) 2024 on Thursday 14 November 2024
ALK: Opsummering fra fysisk investorseminar
Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
Indberetning af ledelsens transaktioner med ALK-Abelló A/S' B-aktier og tilknyttede værdipapirer
